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Abstract: Two new epimeric bibenzylated monoterpenes machaerifurogerol (1a) and 5-epimachaerifurogerol (1b), and four known isoflavonoids (+)-vestitol (2), 7-O-methylvestitol (3),
(+)-medicarpin (4), and 3,8-dihydroxy-9-methoxypterocarpan (5) were isolated from Machaerium
Pers. This plant was previously assigned as Machaerium multiflorum Spruce, from which machaeriols
A-D (6–9) and machaeridiols A-C (10–12) were reported, and all were then re-isolated, except the
minor compound 9, for a comprehensive antimicrobial activity evaluation. Structures of the
isolated compounds were determined by full NMR and mass spectroscopic data. Among the
isolated compounds, the mixture 10 + 11 was the most active with an MIC value of 1.25 µg/mL
against methicillin-resistant Staphylococcus aureus (MRSA) strains BAA 1696, −1708, −1717, −33591,
and vancomycin-resistant Enterococcus faecium (VRE 700221) and E. faecalis (VRE 51299) and
vancomycin-sensitive E. faecalis (VSE 29212). Compounds 6–8 and 10–12 were found to be more
potent against MRSA 1708, and 6, 11, and 12 against VRE 700221, than the drug control ciprofloxacin
and vancomycin. A combination study using an in vitro Checkerboard method was carried out for
machaeriols (7 or 8) and machaeridiols (11 or 12), which exhibited a strong synergistic activity of
12 + 8 (MIC 0.156 and 0.625 µg/mL), with >32- and >8-fold reduction of MIC’s, compared to 12,
against MRSA 1708 and −1717, respectively. In the presence of sub-inhibitory concentrations on
polymyxin B nonapeptide (PMBN), compounds 10 + 11, 11, 12, and 8 showed activity in the range of
0.5–8 µg/mL for two strains of Acinetobacter baumannii, 2–16 µg/mL against Pseudomonas aeruginosa
PAO1, and 2 µg/mL against Escherichia coli NCTC 12923, but were inactive (MIC > 64 µg/mL) against
the two isolates of Klebsiella pneumoniae.
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1. Introduction
The genus Machaerium Pers. (Fabaceae) consists of approximately 130 species, which are primarily
distributed in the tropical Americas [1]. It is a genus of shrubs or lianas and small to medium-sized
trees occurring throughout Southern Mexico to Brazil and Northern Argentina and Peru. These species
are indigenous to all climatic regions ranging from equatorial rainforests to the verges of dry and
cold deserts [2–4]. Several species of this genus are used in traditional medicines are considered
to have multiple medicinal properties. Generally, various plant parts of Machaerium are used as an
antitussive, and the sap is used to cure aphthous ulcers of the mouth [4]. M. floribundum is used to
treat diarrhea and menstrual cramps [4]. The presence of a wide array of secondary metabolites from
Machaerium, including flavonoids, terpenoids, and oxygenated phenolic compounds, together with
their bioactivities, was recently reviewed by Amen et al. (2015) [2].
Earlier studies on one of the Machaerium species (Manuel Rimachi, Y-12161), named M. multiflorum
Spruce, yielded four unique (+)-trans-hexahydrodibenzopyrans (HHDBP), machaeriols A-D, and three
5,6-seco-HHDBPs, machaeridiols A-C [5,6]. An unprecedented structural similarity for the HHDBP
nucleus was observed in machaeriol and hexahydrocannabinol, and the 5,6-seco-HHDBP nucleus in
machaeridiol and dihydrocannabidiol. Since these are the first reports of novel phytocannabinoids
from a higher plant other than Cannabis, a recollection of the plant material was necessary from the
original source. Unfortunately, there is an absence of documentary evidence for the existence of
the species M. multiflorum. This species name was not included in the regional Floras as well as in
major online databases (i.e., the International Plant Names Index (http://www.ipni.org/index.html)
and The Plant List (http://www.theplantlist.org). Therefore, it was assumed that the plant sample was
misidentified and was given the name combination M. multiflorum Spruce in error. An investigation
was carried out on the identity of the plant, and a re-examination of the voucher specimen (Rimachi
# 12161) at the Missouri Botanical Garden (MBG) concluded that this species should be treated only
as an unidentified species of Machaerium Pers., as determined by the collection information (Manuel
Rimachi, Y. 12161) [7].
The significance of the chemistry and biological activity of these aralkyl class of
phytocannabinoid-type compounds led to the re-examination of the n-hexane and DCM fractions of
the stem bark EtOH extract of the original plant material [5,6], as well as previously unexamined root
and leaf extracts, which showed significant enhancement of antimicrobial activity against the various
strains of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin resistant Enterococci
(VRE). MRSA and VRE represent two potential threats to human health. According to the Centers for
Disease Control and Prevention (CDC), MRSA can cause serious health problems, such as bloodstream
infections and pneumonia. CA-MRSA occurs with a higher incidence rate in the United States and in
particular amongst people who are in close physical contact, such as football athletes and childcare
workers [8]. A recent national estimate for invasive MRSA incidence rates showed one in three people
carry S. aureus in their nose and two in 100 people carry MRSA. Enterococci bacteria have the ability to
survive for months in humans and animals. Similar to MRSA, VRE infections are commonly acquired
by hospitalized patients. Enterococcal infections can be lethal, particularly those caused by VRE.
According to the CDC, the number of nosocomial VRE isolates increased in the United States 20-fold,
between 1989 and 1993. VRE is now the second to third most common cause of nosocomial infections
in the USA [9].
In order to acquire substantial quantities of machaeriol A-D (6–9) and machaeridiol A-C
(10–12) for comprehensive antimicrobial evaluations against MRSA and VRE, a reinvestigation
was conducted on stem bark, leaves, and roots of the original plant material. During the course of
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this work, the novel epimeric mixture of bibenzylated furanoid monoterpenes, machaerifurogerol
(1a), and 5-epi-machaerifurogerol (1b), together with the known isoflavons (+)-vestitol (2) and
7-O-methylvestitol (3), and pterocarpans (+)-medicarpin (4) and 3,8-dihydroxy-9-methoxypterocarpan
(5), as well as previously isolated [5,6] machaeriol A-C (6–8) and machaeridiol A-C (10–12), were isolated.
In this study, we report the correction of the previously reported botanical identity of the plant M.
multiflorum, the structure elucidation of compounds 1–5, and comprehensive antimicrobial activities of
compounds 1–8 and 10–12.
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The dried EtOH extract of the stem bark was fractionated with n-hexane, followed by
dichloromethane
(DCM), and resulted in the isolation of compounds 1–5 (Figure 1 and Figure S1)
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FigureFigure
1. Structures
isolated
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1. Structuresof
of the
the isolated
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Chromatographic separation of the DCM fraction 20–24 that led to the isolation of compound 1,
showed a single peak upon LC–MS analysis, which showed a protonated molecular ion peak at m/z
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379.1906 [M + H]+ in its ESI–HRMS, suggesting the molecular formula C28 H29 O3 . A careful analysis
of the 1 H and 13 C NMR spectra (Table 1), and 2D NMR COSY, HMQC, HMBC, and NOESY spectra
(Figures S2–S11) suggested that the compound was a mixture of C-5 epimers 1a and 1b (Figure 2).
Table 1. 1 H and 13 C NMR (in CDCl3 ) data for epimeric compounds 1a and 1b.
Position

1a (Major Epimer)
δc a (J in Hz)

δH

b

(J in Hz)

1b (Minor Epimer)
δc a (J in Hz)

δH b (J in Hz)

HMBC

1
35.2 CH
2.4 (m)
35.4 CH
2.4 (m)
5, 2, 11
2
41.8 CH2
2.72 (m), 1.59 (m)
42.0 CH2
2.39 (m), 1.58 (m)
5, 11
3
77.7 CH
5.32 (dd, 12, 7.6)
77.4 CH
5.59 (dd, 12, 8.0)
2, 1’, 2’, 6’
5
83.1 CH
4.00 (m)
83.3 CH
4.21 (m)
11, 7
6
29.9 CH2
1.24 (br s), 2.4 (m)
29.4 CH2
1.24 (br s), 2.4 (m)
7, 8, 5
7
120.0 CH
5.18 (t, 7.2)
120.0 CH
5.18 (t, 7.2)
9, 10
8
134.5 C
134.4 CH
9
18.2 CH3
1.66 (s)
18.3 CH3
1.66 (s)
7, 8, 10
10
26.1 CH3
1.72 (s)
26.1 CH3
1.72 (s)
7, 8, 9
11
15.5 CH3
1.02 (d, 7.2)
13.9 CH3
1.03 (d, 7.2)
1, 2, 5
1’
113.3 C
114.0 C
2’
155.3 C
155.3 C
3’
104.9 CH
6.83 (br s)
104.9 CH
6.83 (br s)
5’, 4’, 1’
4’
130.6 C
130.8 C
5’
104.9 CH
6.83 (br s)
104.9 CH
6.83 (br s)
3’, 4’, 1’, 7’
6’
155.4 C
155.4 C
7’
154.9 C
154.9 C
8’
101.7 CH
6.89 (br s)
101.6 CH
6.89 (br s)
4’, 7’
9’
129.5 C
129.4 C
Molecules
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7.52 (d, 7.2)
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Figure 2.Figure
Structure
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in mixture.
Table 1. H and C NMR (in CDCl3) data for epimeric compounds 1a and 1b.
Moreover, the NMR
data were found to be partially comparable with the machaeridiol C (11) [6],
(Major Epimer) side chain (δ 1b 7.18–7.52)
(Minor Epimer)
suggesting thePosition
presence of a1abenzofuran
(4H) attached
to the substituted
H
HMBC
δc a (J in Hz)
δH b (J in Hz)
δc a (J in Hz)
δH b (J in3 Hz)
2
resorcinol moiety. The HMBC spectrum (1a; Figure 2) showed J- and J correlations between the H-80
1
35.2 CH
2.4 (m)
35.4 CH
2.4 (m)
5, 2, 11
2
0
0
at δH 6.89 (brs) and
carbons
at C-4
C-7
and5, 154.9,
respectively),
C 130.6
2 the two
41.8 sp
CH2 -hybridized
2.72 (m), 1.59
(m)
42.0
CH2 and2.39
(m),(δ
1.58
(m)
11
0
0
3
77.7of
CHC-4 of
5.32
(dd,resorcinol
12, 7.6)
77.4 CH
5.59 (dd,
8.0)
2, 1’, 2’,
6’ The 1 H NMR
supporting the attachment
the
unit
to the C-7
of12,
benzofuran
ring.
0
0
5
83.1
CH
4.00
(m)
83.3
CH
4.21
(m)
11,
7
spectrum also showed signals at δH 6.83 (2H) for two identical protons (H-3 and H-5 ), suggesting the
6
29.9 CH2
1.24 (br s), 2.4 (m)
29.4 CH2
1.24 (br s), 2.4 (m)
7, 8, 5
presence of C-10 ,270 ,40 ,60 -tetra
substituted
resorcinol ring
with two 5.18
oxygenated
carbons
at C-20 and C-60
120.0 CH
5.18 (t, 7.2)
120.0 CH
(t, 7.2)
9, 10
1
(δC 155.3 and 155.4).
8 In addition,
134.5 C the H NMR spectrum
134.4 (1a)
CH showed signals at δH 4.0 (1H, m, H-5) and
9
18.2 CH
3
1.66
(s)
18.3 CHring,
3
7, 8,d,
10 J = 7.2 Hz, H-11)
5.32 (1H, dd, J = 1.2,
7.6 Hz,
H-3)
for the
tetrahydrofuran
and1.66
at (s)
δH 1.02 (3H,
10
26.1 CH3
1.72 (s)
26.1 CH3
1.72 (s)
7, 8, 9
for a Me-group. The
HMBC
(Figure
3)
spectrum
showed
correlations
between
the
H-3
(δH 5.32) and the
11
15.5 CH3
1.02 (d, 7.2)
13.9 CH3
1.03 (d, 7.2)
1, 2, 5
1

1’
2’
3’
4’
5’
6’
7’

113.3 C
155.3 C
104.9 CH
130.6 C
104.9 CH
155.4 C
154.9 C

13

6.83 (br s)
6.83 (br s)

114.0 C
155.3 C
104.9 CH
130.8 C
104.9 CH
155.4 C
154.9 C

6.83 (br s)

5’, 4’, 1’

6.83 (br s)

3’, 4’, 1’, 7’

supporting the attachment of C-4′ of the resorcinol unit to the C-7′ of benzofuran ring. The 1H NMR
spectrum also showed signals at δH 6.83 (2H) for two identical protons (H-3′ and H-5′), suggesting
the presence of C-1′,2′,4′,6′-tetra substituted resorcinol ring with two oxygenated carbons at C-2′ and
C-6′ (δC 155.3 and 155.4). In addition, the 1H NMR spectrum (1a) showed signals at δH 4.0 (1H, m, H5) and 5.32
dd, J = 1.2, 7.6 Hz, H-3) for the tetrahydrofuran ring, and at δH 1.02 (3H, d, J = 7.2
Hz,
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δC 15.5)
the(δtetrahydrofuran
H methyl
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1
13
83.1),
supporting
the
attachment
of
the
methyl
(C-11,
δ
15.5)
to
the
tetrahydrofuran
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C
at C-1 (δC 35.2). The H, C, and 2D NMR spectra supported
the presence of the 2-methylbut-2-ene
1 H, 13 C, and 2D NMR spectra supported the presence of the 2-methylbut-2-ene unit. This was
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confirmed
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carbonsspectrum,
at C-5, C-7,which
and C-8
(δC 83.1,
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of
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tetrahydrofuran
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relativevia
configurations
at C-1,
configurations
at C-1, C-3,
and
of the tetrahydrofuran
wereThe
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careful analysis
of
C-3,
andcorrelations
C-5 of the tetrahydrofuran
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careful for
analysis
of NOESY
correlations
for 1a.
NOESY
for 1a. In the NOESY
spectrumvia
(assigned
1a), H-5
(δH 4.0) showed
correlation
In
theH-1
NOESY
(assigned
for 1a),
H-5 (δH 4.0)
with of
H-1the
(δHthree
2.4) and
H-3
with
(δH spectrum
2.4) and H-3
(δH 5.32),
indicating
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cofacial correlation
(β)-orientation
groups.
(δ
cofacial
(β)-orientation
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groups.
Additionally,
NOESY
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Additionally,
NOESYthe
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H 5.32), indicating
cross
peaks
between
H-1
(δ
2.4.)
and
H-3
(δ
5.32),
which
supported
their
presence
in
the
same
their presence in the same Hplane of the molecule
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(1H,
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(+)-medicarpin and 3,8respectively, previously reported from Machaerium vestitum and Cuban propolis [10,11]. Compounds 4
and 5 were also reported from Cuban propolis [11]. The 1 H and 13 C NMR spectroscopic data
(see Table S1) of compounds 2–5 were in agreement with those reported [11,12]. In addition, examination
of the leaves of Machaerium sp. also yielded compounds 6–8 and 10–12, as well as their presence in
the root extract. The identities of compounds 6–12 were established by NMR spectra and by direct
comparison with authentic samples (TLC, HPLC/ LC–MS).
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2.3. Antimicrobial Activity against Gram-Positive Species and Fungi
The availability of machaeriols A-C (6–8) and machaeridiols (10–12) [5,6] offered the opportunity
to carry out a comprehensive investigation of antimicrobial activity. Among the tested fractions,
DCM-25-32 (enriched with compounds 8 and 10–12) and DCM-10-15 (enriched with compound
12) were the most active against bacteria S. aureus, and methicillin-resistant S. aureus (MRSA),
and the fungi Candida glabrata, C. krusei, and Cryptococcus neoformans, with IC50 values of <0.8, <0.8,
<0.8, 5.35, <0.8 µg/mL, and <0.8, 1.95, 3.0, 6.07, 12.58 µg/mL, respectively (Table 2). Antibacterial
activities of 6–8, 10–12, and a mixture 10 + 11 (1:1) were evaluated against methicillin-resistant S.
aureus (ATCC 1708, 1696, and 1717), the ex vivo MRSA XEN31 strain, and vancomycin-resistant
Enterococci (VRE; Enterococcus faecium ATCC 700221), low-level VRE (E. faecalis ATCC 51299), and the
vancomycin-sensitive strain (VSA; E. faecalis ATCC 29212) (Tables 3 and 4). Compound 11 and mixture
10 + 11 (1:1) showed the most potent activity against MRSA BAA 1696, BAA 1708, BAA 1717, and BBA
33591 with IC50 /MIC/MBC values of 0.43/1.25/5 µg/mL, 0.38/1.25/1.25 µg/mL, 0.38/1.25/2.5 µg/mL,
0.71/1.25/1.25 µg/mL; and 0.41/1.25/10 µg/mL, 0.34/1.25/1.25 µg/mL, 0.39/1.25/1.25 µg/mL and
0.61/1.25/10 µg/mL, respectively. On the other hand, compound 8 and mixture 10 + 11 were found to be
the most potent against E. faecium ATCC 700221 and E. faecalis ATCC 51299, (VRE) and E. faecalis ATCC
29212 (VSE) with IC50 /MIC/MBC of 0.48/1.25/2.5 µg/mL, 1.02/1.25/5 µg/mL and 1.16/2.5/2.5 µg/mL;
and 0.49/1.25/2.5 µg/mL, 0.70/1.25/5 µg/mL, and 0.72/1.25/5 µg/mL, respectively (Tables 3 and 4).
The activities of compounds 6–8 and 10–12 were found to be more potent than ciprofloxacin and
vancomycin against the MRSA BBA 1708 strain, while 6, 8, and 10 + 11 were more active against VRE
700221 than the positive controls.
Table 2. Antimicrobial activity (IC50 in µg/mL) of Machaerium DCM fractions a .
C. glabrata

C. krusei

C. neoformans

S. aureus

MRSA

VRE
29212 b

VRE
51299 c

VRE
700221 d

>20
>20
6.07
<0.8
>20
>20
>20
>20
>20

>20
>20
12.58
5.35
>20
>20
>20
>20
>20

>20
4.26
<0.8
<0.8
>20
>20
4.41
>20
>20

6.09
<0.8
1.95
<0.8
>20
9.91
4.51
4.29
4.5

5.64
0.81
3
<0.8
>20
>20
10.62
4.55
4.41

11.41
5.68
3.70
5.41
11.39
-

1.89
1.65
1.34
8.52
14.49
-

3.47
2.95
<0.8
2.94
4.52
9.97
-

DCM-1-8
DCM-10-15
DCM-12
DCM-25-32
DCM-56
DCM-1-8-A-31
DCM-1-8-A-41
DCM-1-8-A-63
DCM-1-8-A-167
a

IC50 is the concentration causing 50% growth inhibition; MIC (minimum inhibitory concentration) is the lowest
concentration that allows no growth; MFC (minimum fungicidal concentration) or MBC (minimum bactericidal
concentration) is the lowest concentration at kills the test organism; b Vancomycin sensitive, c Low-level vancomycin
resistant. d Vancomycin resistant strain; -: not active at the highest test concentration of 20 µg/mL.

Table 3. Anti-MRSA activities (in µg/mL) of compounds 6–8 and 10–12.
MRSA
BAA-1708

MRSA
BAA-1717

MRSA 33591

MRSA
BAA-1696

MRSA XEN31

Compound

IC50 /MIC/MBC

IC50 /MIC/MBC

IC50 /MIC/MBC

IC50 /MIC/MBC

IC50/MIC/MBC

6
7
8
10
11
12
10 + 11
Ciprofloxacin
Vancomycin
Methicillin
Cefotaxime

10.61/-/5.36/-/0.69/1.25/1.25
1.03/2.5/5
0.38/1.25/1.25
1.52/5/5
0.34/1.25/1.25
-/-/>20/>20/>20
2.2/50/50
0.35/0.63/0.63

I1.93/-/3.29/-/0.72/1.25/10
1.03/2.5/5
0.38/1.25/2.5
0.38/2.5/5
0.39/1.25/1.25
0.14/0.63/1.25
0.73/1.25/>20
0.35/0.63/0.63

_
NT
NT
NT
0.71/1.25/1.25
1.57/2.5/5
0.61/1.25/10
0.04/0.16/0.31
0.47/1.25/5.0
NT

11.87/-/14.64/-/0.71/2.5/2.5
1.07/2.5/2.5
0.43/1.25/5
1.40/5/10
0.41/1.25/10
6.17/-/0.37/0.62/>20
2.54/50/50
2.47/12.5/25

3.50/-/4.95/20/20
0.46/1.25/2.5
1.01/2.5/5
0.33/0.63/1.25
1.64/5/10
0.32/0.63/1.25
0.10/0.31/0.63
NT
0.38/1.56/3.13
0.29/0.78/3.13

NT not tested.
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Table 4. Anti-VRE activities (in µg/mL) of compounds 6–8 and 10–12.
Enterococcus faecalis
ATCC 29212 a

Enterococcus faecalis
ATCC 51299 b

Enterococcus faecium
ATCC 700221 c

Compound

IC50 /MIC/MBC

IC50 /MIC/MBC

IC50 /MIC/MBC

6
8
12
10 + 11
Ciprofloxacin
Vancomycin
Methicillin

3.51/-/1.16/2.5/2.5
2.99/5/10
0.72/1.25/5
0.25/0.78/6.25
0.73/1.25/>20
15.3/25/50

18.79/-/1.02/1.25/5
2.96/5/10
0.70/1.25/5
0.22/0.39/6.25
3.8/10/>20
14.2/50.0/50.0

0.55/1.25/10
0.48/1.25/2.5
1.91/2.5/5
0.49/1.25/2.5
>20/>20/>20
>20/>20/>20
>20/>20/>20

a

vancomycin sensitive; b low-level vancomycin resistant; c vancomycin resistant.

2.4. Antimicrobial Combination Studies
In light of the strong antimicrobial activity of the DCM fraction 25–32, which is enriched with
compounds 8, 10–12 (Table 3), a combination study using an in vitro Checkerboard method [13,14] was
carried out for machaeriol (7 or 8) and machaeridiol (11 or 12), to evaluate the synergy of combination
treatment against the strains of MRSA and Enterococcus (VRE) (Table 4). Among these compounds,
a combination of machaeridiol B (12; at MIC 5 µg/mL) and machaeriol C (8; at 12 MIC 1.25 µg/mL)
exhibited a potent activity, with the MIC values of 0.156 and 0.625 µg/mL exhibiting a >32- and >8-fold
reduction of MICs, compared to those observed for 12, against MRSA 1708 and MRSA 1717 strains.
When these two compounds were tested with an inverse concentration (i.e., MIC of 8; 2.5 µg/mL + 12
MIC of 12; 2.5 µg/mL), a strong synergism was also observed, but to a lesser extent. When tested against
VRE (E. faecium 700221), this combination showed synergism with the MIC values of 1.25 µg/mL,
a >4-fold reduction of MIC compared to 12 (Table 5).
Isobologram showing synergistic activity of the combination of compounds 8 and 12 in MRSA
1708 (red) and 1717 (blue) are presented in Figure 4. The green series represents the additivity
line of compounds 8 and 12 (green dots represent the MIC of each compound alone; the green line
represents all possible additive combinations). The red (MRSA 1708) and blue (1717) dots represent the
combination of compounds 8 and 12, and show that they fell below the additivity line (the combination
of the compounds produces a synergistic effect beyond additivity). This synergism between machaeriol
(HHDBP) and machaeridiol (seco-HHDBP) could be due to different molecular targets affected by
these two molecules. A combination study of compounds 8 and 12 with antibiotics, either methicillin
or ciprofloxacin, did not show any additive or synergistic effects.
Table 5. Combination study (MIC in µg/mL) a of compounds 7, 8, 11, and 12 by Checkerboard assay
against MRSA and VRE.
Compound
7
8
12
11
8 + 12 (+2.5 µg/mL)
12 + 8 (+1.25 µg/mL)

MRSA
1717

MRSA
33591

MRSA
1696

MRS
XEN31

Ef 29212 b

Ef 51299 c

Ef 700221 d

20
2.5
5
20
0.625
(↓4X)
0.156
(↓32X)

>10
2.5
5
20
0.625
(↓4X)
0.625
(↓8X)

NT
2.5
5
NT
1.25
(↓2X)
1.25
(↓4X)

10
2.5
5
10
0.625
(↓4X)

20
1.25
5
10

NT

NT
2.5
>5
NT
1.25
(↓2X)
2.5
(↓2X)

NT
1.25
5
NT
0.625
(↓2X)

NT

NT
2.5
5
NT
1.25
(↓2X)
2.5
(↓2X)

12 + 8 (+0.625 µg/mL)

NT

NT

11 + 7 (+2.5 µg/mL)

5.0
(↓4X)
>1.25
2.5 (=)
>5 (=)
50
>20

10.0
(↓2X)
NT
NT
NT
1.25

DAPG e
8 + DAPG (+0.63 µg/mL)
12 + DAPG (+0.63 µg/mL)
Methicillin
Vancomycin
a

MRSA
1708

NT
NT
NT
NT
NT
1.25

2.5
(↓2X)
5.0
(↓2X)
NT
NT
NT
50
0.62

NT

NT
2.5
(↓4X)
NT
NT
NT
1.56
NT

NT
1.25
(↓4X)

NT

NT

NT

NT

NT

NT
NT
NT
25
1.25

NT
NT
NT
50.0
10

>1.25
1.25 (=)
5 (=)
>20
>20

In general, when the MIC of each compound decreased ≥4X in the presence of the other, it is considered synergistic;
reduction of MIC in parentheses; b Vancomycin-sensitive Enterococcus faecalis; c Low-level vancomycin-resistant
Enterococcus faecium; d Vancomycin-resistant Enterococcus faecium; e Diacetylphloroglucinol; NT: Not tested.
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of 128 µg/mL. However, when the outer membrane was permeabilized using the
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membraneaeruginosa
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to
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and E.displayed
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and
in P.
aeruginosa
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P. aeruginosa
strain
PMBN, suggesting the target/pathway might be missing or modified in this species.
NCTC 13437 is a near-pan drug resistant strain, and this was reflected in the MICs to compounds
6 + 7, 10 + 11, 11, and 12, although 8 had an MIC of 8 µg/mL in the presence of PMBN. None of
the compounds displayed activity in the two K. pneumoniae strains, even in the presence of PMBN,
suggesting the target/pathway might be missing or modified in this species.
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Table 6. Gram-negative MIC Values (in µg/mL) of compounds 6–8 and 10–12 in the presence of the membrane permeabilizer polymyxin-B-nonapeptide at 30 µg/mL.
Klebsiella
pneumoniae
NCTC13368

Klebsiella
pneumoniae
M6

Acinetobacter
baumannii
AYE

Acinetobacter
baumannii
ATCC17978

Pseudomonas
aeruginosa
PAO1

Pseudomonas
aeruginosa
NCTC13437

Escherichia coli
NCTC12923

Compound

MIC

MIC

MIC

MIC

MIC

MIC

MIC

6 + 7 +PMBN
10 + 11 +PMBN
11 + PMBN
12 + PMBN
8 + PMBN
Ciprofloxacin a
Ceftazidime a
Gentamicin a

>64
>64
>64
>64
>64
0.5
>128
4

>64
>64
>64
>64
>64
≤0.125
0.25
0.25

>64
8
2
4
8
128
>128
>512

>64
0.5
1
2
2
0.5
<0.5
0.5

32
2
4
16
2
0.5
1
4

64
64
64
64
8
64
>128
256

>64
2
2
2
2
≤0.125
0.5
1

a

MICs in the absence of PMBN.
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3. Materials and Methods
3.1. General Experimental Procedures
Optical rotations were recorded at ambient temperature using a Rudolph Research Analytical
Autopol IV automatic polarimeter. IR spectra were obtained using a Bruker Tensor 27 instrument.
NMR spectra were acquired on a Varian Mercury 400 MHz NMR spectrometer at 400 (1 H) and 100 MHz
(13 C) in CDCl3 , using the residual solvent as an internal standard. Multiplicity determinations (DEPT)
and 2D NMR spectra (HMQC, HMBC, NOESY) were obtained using the standard Bruker pulse
programs. ESI-HRMS were acquired by direct injection using a Water Xevo G2-S TOF with electrospray
ionization (ESI). TLC was carried out on pre-coated silica gel 60 F254 (EMD Chemicals Inc, Darmstadt,
Germany) using toluene-EtOAc (9:1) and n-hexane-EtOAc (7.5:2.5) as solvents. Centrifugal preparative
TLC (CPTLC, using a Chromatotron, Harrison Research Inc. model 8924, tagged with a fraction
collector) was carried out on 6 mm custom-made RP C18 silica gel [15], and silica gel P254 (Analtech) 1,
2, and 4 mm rotors, using H2 O-MeOH, EtOAc-:n-hexane, and CHCl3 as eluents. SPE cartridges C18
(Supelco Inc., Bellefonte, PA, USA) were used in the fractionation work. Purifications were performed
on prep-HPLC (silica gel-100 A 250 × 15.00, 5 µM; Phenomenex Luna, Torrance, CA, USA) using an
HPLC Delta Prep 4000 equipped with a dual wavelength detector Model 2487 adjusted at 210 and
254 nm (Waters Corporation, Milford, MA, USA), Preparative HPLC was carried out on Waters LC
module I plus, using Phenomenex C18, 22 mm, λ 254, flow 15 mL/min, 0–2 min [90% H2 O; 10% MeCN],
2–45 min, 10% MeCN→ 100% MeN, 45–50 min 100% MeCN]. Samples were dried using a Savant
Speed Vac Plus SC210A concentrator. The compounds were visualized by spraying the TLC plates
with 1% vanillin-H2 SO4 spray reagent.
3.2. Plant Material
The stem bark, leaves, and roots of Machaerium Pers. (Manuel Rimachi, Y.-12161), previously identified
as M. multiflorum Spruce [5] by (Late) Professor Sydney T. McDaniel, was collected in November, 1997,
from open sandy forest near Loreto (Maynas), Peru. The voucher specimen (Manuel Rimachi Y. 12161) is
deposited at the Missouri Botanical Garden (http://www.tropicos.org/Specimen/100326687).
3.3. Extraction and Isolation of Compounds from Stem Bark and Leaves
The powdered stem bark (0.5 kg) was extracted by percolation with 95% EtOH (3 × 2 L) and
the combined extracts were evaporated under reduced pressure (yield 17.7 g). A portion of the
dried EtOH extract (15 g) was percolated with n-hexane, followed by DCM, and finally the residual
extract was washed with MeOH (each 200 mL × 3). The n-hexane, DCM, and MeOH fractions were
separately filtered and dried, which afforded 3.8, 8.9, and 4.5 g, respectively. The antimicrobial activity
was detected in the DCM fraction (IC50 < 20 µg/mL against S. aureus and MRSA). A portion of the
dried DCM fraction (1.65 g) was fractionated by CPTLC with a Chromatotron®instrument, using a
4 mm custom-made C18 RP silica gel ChromatoRotorTM [15], eluting with a gradient of 60% to 100%
MeCN-H2 O to afford 30 fractions. The fractions were pooled by TLC analyses.
Fractions 1–8 (475 mg) were combined and further subjected to CPTLC, using a 4 mm silica gel
P254 disc, and gradient elution with MeCN:DCM. Elution with 2% MeCN:DCM afforded medicarpin
(4; 4.5 mg), followed by elution with 4% MeCN:DCM, which gave 3,8-dihydroxy-9-methoxy-pterocarpan
(5; 7.5 mg), and finally elution with 5% MeCN:DCM yielded vestitol (2; 9.8 mg). The combined fractions
10–15 (70 mg) was subjected to preparative C18 RP-HPLC, using 90% MeCN:H2 O as solvent, which
afforded machaeridiol B (12), followed by machaeridiol A (10) and machaeridiol C (11). Similarly,
combined fractions 25–32 (100 mg) was also separated by preparative C18 RP-HPLC, which afforded
additional quantities of 10–12 [total yields: 10 (10 mg), 11; (18 mg), 12 (21 mg)] and machaeriol C
(8; 34.6), however, the minor compound machaeriol D (9) could not be re-isolated due to a paucity of
material. Further elution with 75% MeCN:H2 O afforded 13 fractions, which contained the mixture
of two compounds 6 + 7, (50 mg). The mixture was then separated by preparative C18 RP-HPLC
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(column: ODS prodigy 10µ, 250 × 10 mm; detector: UV-254 nm), using 95% MeCN:H2 O as solvent,
which afforded 6 (16 mg), followed by 7 (16 mg). Finally, the dried n-hexane fraction (77 mg) was
subjected to CPTLC, using a 2 mm C18 RP rotor, and eluted with 65% MeCN:H2 O, which afforded
7-O-methylvestitol (3; 8 mg). A sub-fraction of DCM (15 mg) was subjected to prep-HPLC (Waters LC
module I plus, using Phenomenex C18 , 2 mm), which afforded compound 1a+1b (5 mg). The structures
of (+)-vestitol (2), 7-O-methylvestitol (3), (+)-medicarpin (4) and 3,8-dihydroxy-9-methoxypterocarpan
(5) were determined by physical and spectroscopic data (1 H and 13 C NMR, see SI 1), and also by
comparison with those reported [11,12]. The structures of the re-isolated compounds 6–8 and 10–12
were identified by NMR data [5,6] and by direct comparison (TLC, HPLC/LC–MS) with their respective
authentic samples available in our laboratories. Finally, powdered leaves (560 g) and root bark (50 g)
of Machaerium sp. were extracted using the method described previously [5,6], and compounds 6–8
and 10–12 were isolated from leaves as describe below.
The powdered leaf was percolated with n-hexane, followed by DCM and EtOH (each 3 × 2 L)
to yield 5, 14, and 9 g of extracts, respectively. A portion of the DCM extract (10 g) was subjected
to reversed phase (RP) cartridge (10 G, 60 mL Giga tube), and eluted with MeCN-H2 O to afford 30
fractions. The combined fractions 20–21 (102 mg; eluted by 60–65% MeCN-H2O) were subjected to
centrifugal preparative thin layer chromatograph (CPTLC, 1 mm Si gel P254 disc), eluting with 0.5–1%
MeCN-DCM to yield 12 (11.4 mg). Fraction 22 (60 mg; eluted with 75% MeCN-H2 O) was further
subjected to CPTLC (1 mm RP-C18 ChromatoRotor), eluted with 50–100% H2 O-CH3 CN to afford
115 fractions, of which fractions 42–45 and 90–115 eluting with 80% and 90% MeCN-H2 O yielded 10
(2.7 mg) and 11 (4.5 mg), respectively. Combined fractions 46–89 (28.4 mg) were enriched with 12
(+ traces of 10 + 11). Similarly, RP cartridge purified fractions 23 and 24 (60 and 70 mg; eluted with 70
and 80% MeCN-H2 O, respectively) were further purified (1 mm RP-C18 ChromatoRotor) by eluting
separately with 50–100% H2 O-MeCN to yield a mixture of 8 + 10 + 11 (32 mg and 31 mg respectively).
The above enriched mixtures were further purified preparative RP-HPLC, using 90% MeCN-H2 O as
solvent to afford compounds 12, 11 + 12, 11, and 8 (5, 32, 4 and 31.7 mg, respectively).
A portion of n-hexane extract (2.5 g) was fractionated with CPTLC (6 mm, Si gel P254 disc) eluting
with 5% DCM in hexane to yield 10 fractions. The fractions 3–7 (840 mg) that enriched with compounds
6 and 7 were combined and further attempted to purify with an additional CPTLC (4 mm, Si gel P254
disc) eluting with 5% DCM in hexane to yield semi-pure 6 (40 mg), 6+7 (50 mg), and semi-pure 7
(6 mg). In addition, the presence of these compounds in leaves, stem bark, and root extracts were
confirmed by HPLC and LC–MS (vide infra).
3.4. Machaerifurogerol (1a) and 5-epi-Machaerifurogerol (1b)
Amorphous solid; [α]26 D +5.8 (c 0.05, MeOH); IR (KBr) υ max 3341 (OH), 2924, 1631, 1574, 1452,
1248, 961, 801, 613, 591 cm−1 ; 1 H and 13 C NMR, see Table 1; HRESIMS m/z 379.1906 [M + H]+ (calcd. for
C24 H27 O4 , 379.1865).
3.5. Identification of Compounds 6–8 and 10–12 by LC–MS
LC–MS analysis was carried out on an Agilent system using Luna 5 µ C18 (2), 150 × 4.6 mm,
λ 254, flow 1 mL/min, gradient 0–2 min [95% H2 O; 5% MeCN], 2–30 min, 5% MeCN→ 100% MeCN,
30–35 min 100% MeCN, 35–45 min [95% H2 O; 5% MeCN]. The retention times (Rt ) of the compounds 6
(m/z 349.2 [M + H]+ ; C24 H29 O2 ), 8 (365.2 [M + H]+ ; C24 H29 O3 ), 7 (363.2 [M + H]+ ; C24 H27 O3 ), 10 (349.2
[M + H]+ ; C24 H29 O2 ); 11 (363.2 [M + H]+ ; C24 H27 O3 ), and 12 (365.2 [M + H]+ ; C24 H29 O2 ) were found
to be 4.4, 4.5, 9.9, 10.0, 9.4, and 9.7 min−1 , respectively. Compounds 6–9 and 10–12 were identified from
leaves, stem bark, and root extracts through HPLC and LC–MS.
3.6. Antimicrobial Assays
All organisms were obtained from the American Type Culture Collection (Manassas, VA,
USA) or the National Collection of Type Cultures (Colindale, UK), unless specified otherwise.
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These included the yeasts Candida albicans ATCC 90028, C. glabrata ATCC 90030, and C. krusei
ATCC 6258; the fungi Cryptococcus neoformans ATCC 90113 and Aspergillus fumigatus ATCC 204305;
and the bacteria Escherichia coli ATCC 35218, NCTC 12923, Klebsiella pneumoniae NCTC 13368,
M6 (Colindale, UK), Acinetobacter baumannii AYE (ATCC BAA-1710), ATCC 17978, Pseudomonas
aeruginosa ATCC 27853, PAO1 (Manoil collection, University of Washington, Washington, DC,
USA), NCTC 13437, Mycobacterium intracellulare ATCC 23068, methicillin-resistant Staphylococcus
aureus ATCC 33591 (MRSa), USA-300 MRSa (ATCC BAA-1717), USA-400 MRSa (ATCC BAA-1696),
Mupirocin-resistant S. aureus (ATCC BAA-1708), Enterococcus faecium ATCC 700221 (VRE), E. faecalis
ATCC 29212 (Vancomycin-sensitive) and Enterococcus faecium ATCC 51299 (Vancomycin-intermediate).
Drug controls ciprofloxacin, methicillin and vancomycin (ICN Biomedicals, Aurora, OH, USA)
for bacteria and amphotericin B (ICN Biomedicals) for yeasts and fungi were included in each
assay. Susceptibility testing was performed using a modified version of the CLSI (formerly NCCLS)
method [16–18]. M. intracellulare was tested using a modified Franzblau method [18]. Samples were
serially diluted in 20% DMSO/saline and transferred in duplicates to 96-well flat-bottomed microplates.
Microbial inocula were prepared by correcting the OD630 of microbe suspensions in incubation broth
to give final target inocula. All organisms were read at either 530 nm, using the Biotek Powerwave XS
plate reader (Bio-Tek Instruments, Winooski, VT, USA) or 544ex/590em, (M. intracellulare, A. fumigatus)
using the Polarstar Galaxy Plate Reader (BMG Lab Technologies, Ortenburg, Germany), prior to and
after incubation. Minimum fungicidal or bactericidal concentrations were determined by removing
5 µL from each clear well, followed by transferring to agar, and incubating. The MFC/MBC was defined
as the lowest test concentration that kills the organism (allows no growth on agar).
Gram-negative MICs were determined using the CLSI microbroth dilution method, modified as
described previously [19]. Bacteria were added at a starting concentration of 5 × 105 cfu/mL and
incubated for 20 h at 37 ◦ C in the dark. Absorbance at OD600 was then read using the CLARIOstar
plate reader (BMG Lab Technologies, Germany). The MIC was defined as the lowest concentration
where visible growth could not be detected, equivalent to an OD600 of 0.1. MICs were also determined
in the presence of the membrane permeabilizer, polymyxin-B-nonapeptide (PMBN) following the
same method, with an additional step; after the 2-fold dilution of compound was prepared and
before the bacteria were added, PMBN was added to all wells at a final concentration of 30 µg/mL.
This concentration was shown to not significantly inhibit growth of the test panel.
3.7. Antimicrobial Combination Study by Checkerboard Method
The combination study of the compounds was carried out using a standard Checkerboard
method [13,14]. Strains were grown on Eugon agar at 35 ◦ C, prior to assays. Test samples were
dissolved in DMSO (2 mg/mL) to the desired concentrations, and serially-diluted with 20% DMSO/saline.
Samples were transferred to 96 well assay plates (10 µL) in a checkerboard layout. Inocula were
prepared by suspending growth from agar in 0.9% saline, determining the OD630 , and correcting in
incubation broth (cation-adjusted Mueller-Hinton, Difco) to afford 5 × 105 colony forming units per mL,
after addition to samples (180 µL) using standard inocula calculations. Final sample test concentrations
were 1/100th the DMSO stock concentrations. The assay plates were read at 530 nm prior to and after
incubation at 35 ◦ C for 18–20 h. IC50 s of each test compound were calculated using the XLfit 4.2 software
(IDBS, Alameda, CA, USA) using the fit model 201. After incubation, all 96 wells were also pinned to
Eugon Agar and incubated at 35 ◦ C overnight to determine bactericidal activity. Fractional inhibitory
concentrations (FICs) were calculated to evaluate possible synergy with FICS < 0.5 synergistic.
4. Conclusions
Based on our investigation carried out on the identity of the plant, and a re-examination of
the voucher specimen (Rimachi # 12161) at the MOBOT, it can now be concluded that this species
should be treated only as an unidentified species of Machaerium Pers., as determined by the collection
information (Manuel Rimachi, Y. 12161). This appears to be the first report of macharifurogerol
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(1a) and its epimer 1b from a natural source. In addition, the isolation of isoflavons (2 and 3) and
pterocarpans (4 and 5) from this Machaerium species (Rimachi 12161) illustrated that these isoflavonoids
are typical chemotaxonomic markers of the genus Machaerium [11,12]. Machaeriols and its biogenetic
precursor machaeridiols are only isolated from this species (#12161) from the genus Machaerium, which
are analogous to hexahydrocannabinol (HHC) and dihydrocannabidiol base skeletons of Cannabis
and its variants, in higher plants [6]. The only other bibenzyl analogue of ∆9 -THC, perrottetinen,
was previously reported from the liverwort Radula perrottetii [20]. It is intriguing to note that the
strong MRSA and VRE inhibitory activities, together with their antiparasitic activities [5,6] of the
isolated compounds of Machaerium (12161) is contributed by HHDBP machaeriols and their 5,6-seco
analogs machaeridiols. The stereo-specific total synthesis of machaeriol A-D (6–9) and mechaeridiol
B (12) was reported [21–24]. In addition, analogs of machaeriols and related HHC were recently
synthesized, which showed anticancer activity [25]. It was anticipated that these phytocannabinoids
could serve as potential template for anti-MRSA and anti-VRE lead candidates, because of their
inherent inhibitory activities alone, as well as strong synergistic activity when tested in combination
with machaeriol and machaeridiol. The observation of significant activity in permeabilized multidrug
resistant Gram-negative pathogens, also offers the potential for optimization of the chemical scaffold
to generate analogues with better cell permeability. These compounds might provide important new
leads for WHO priority Gram-negative bacterial pathogens.
Supplementary Materials: The following are available online, NMR and HRMS spectra (Figures S1–S11) of
compound 1, and Table for NMR data (Table S1) of compounds 2–5 are provided in supporting information.
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